Pharmacy Website
Clinic Website

Intelligence » Multiple Sclerosis » Last Week

Subscribe to get latest posts via email or subscribe to a RSS feed.

Link Between Gut Flora and Multiple Sclerosis Discovered

Thursday, October 11, 2018 -- NewsMultiple sclerosis is an autoimmune disease in which the body's own immune system attacks and damages the protective coating around nerve cells.Contributed Author: University of ZurichTopics: Drug Discovery and Development

FDA to Review Siponimod for Secondary Progressive Multiple Sclerosis

Wednesday, October 10, 2018 -- The NDA is based on data from the EXPAND study, a randomized, double-blind, placebo-controlled Phase 3 study in 1652 participants living with SPMS.

[Research Articles] GDP-L-fucose synthase is a CD4+ T cell-specific autoantigen in DRB3*02:02 patients with multiple sclerosis

Wednesday, October 10, 2018 -- Multiple sclerosis is an immune-mediated autoimmune disease of the central nervous system that develops in genetically susceptible individuals and likely requires environmental triggers. The autoantigens and molecular mimics triggering the autoimmune response in multiple sclerosis remain incompletely understood. By using a brain-infiltrating CD4+ T cell clone that is clonally expanded in multiple sclerosis brain lesions and a systematic approach for the identification of its target antigens, positional scanning peptide libraries in combination with biometrical analysis, we have identified guanosine diphosphate (GDP)–l-fucose synthase as an autoantigen that is recognized by cerebrospinal fluid–infiltrating CD4+ T cells from HLA-DRB3*–positive patients. Significant associations were found between reactivity to GDP-l-fucose synthase peptides and DRB3*02:02 expression, along with reactivity against an immunodominant myelin basic protein

Drug Shows Promise for Progressive Multiple Sclerosis

Wednesday, October 10, 2018 -- An oral therapy called ibudilast significantly reduced the rate of brain tissue loss in patients with progressive multiple sclerosis, according to the results of a phase II trial.

Multiple Sclerosis Comorbidities Affect Work Participation, Daily Function

Thursday, October 11, 2018 -- Surveys were given out to individuals in the Australian Multiple Sclerosis Longitudinal Study between August and December 2016.

Ozanimod Reduces Severe Relapses in Multiple Sclerosis More Than Interferon Beta-1a

Thursday, October 11, 2018 -- Treatments were evaluated for either 1 year (SUNBEAM) or 2 years (RADIANCE).

Sexual Dysfunction Prevalent but Underrecognized in Multiple Sclerosis

Thursday, October 11, 2018 -- Sexual health is rarely addressed during patient care and research in multiple sclerosis.

Use of Disease Modifying Therapies for Multiple Sclerosis Has No Ill Effect on Pregnancy Outcomes

Thursday, October 11, 2018 -- Patients were divided into 3 groups: patients not treated in the 3 months before pregnancy, patients treated in the 3 months before pregnancy, and patients treated during pregnancy.

Poor Functional Outcomes Tied to Depressive Symptoms in Multiple Sclerosis

Tuesday, October 09, 2018 -- Higher depressive symptoms in patients with multiple sclerosis was associated with lower employment and processing speed.